ESR1 and breast cancer: Furthermore, Swinstead et al. demonstrated that both ligand-bound ER and GR could reprogram the chromatin landscape in breast cancer cells and then recruit FOXA1 to a subset of binding sites that were inaccessible to FOXA1 prior to ligand stimulation [57].